<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03190265</url>
  </required_header>
  <id_info>
    <org_study_id>J1790</org_study_id>
    <secondary_id>IRB00137389</secondary_id>
    <nct_id>NCT03190265</nct_id>
  </id_info>
  <brief_title>Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer</brief_title>
  <official_title>A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the safety and clinical activity of nivolumab and&#xD;
      ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine&#xD;
      followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor marker kinetics (CA19-9)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab, Ipilimumab, CRS-207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.</description>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
    <other_name>CY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.</description>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
    <arm_group_label>Nivolumab, Ipilimumab, CRS-207</arm_group_label>
    <other_name>anti-PD-1, OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.</description>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
    <arm_group_label>Nivolumab, Ipilimumab, CRS-207</arm_group_label>
    <other_name>YERVOY®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVAX Pancreas Vaccine</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.</description>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
    <other_name>GVAX, PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.</description>
    <arm_group_label>CY, Nivolumab, Ipilimumab, GVAX, CRS-207</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRS-207</intervention_name>
    <description>Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.</description>
    <arm_group_label>Nivolumab, Ipilimumab, CRS-207</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Have histologically or cytologically proven adenocarcinoma of the pancreas.&#xD;
&#xD;
          3. Have metastatic disease.&#xD;
&#xD;
          4. Have disease progression.&#xD;
&#xD;
          5. Patients with the presence of at least one measurable lesion.&#xD;
&#xD;
          6. Patient's acceptance to have a tumor biopsy of an accessible lesion at baseline and on&#xD;
             treatment if the lesion can be biopsied with acceptable clinical risk (as judged by&#xD;
             the investigator).&#xD;
&#xD;
          7. ECOG performance status 0 or 1&#xD;
&#xD;
          8. Life expectancy of greater than 3 months.&#xD;
&#xD;
          9. Patients must have adequate organ and marrow function defined by study-specified&#xD;
             laboratory tests.&#xD;
&#xD;
         10. Must use acceptable form of birth control while on study.&#xD;
&#xD;
         11. Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history or evidence of brain metastases.&#xD;
&#xD;
          2. Had surgery within the last 28 days&#xD;
&#xD;
          3. Had chemotherapy, radiation, or biological cancer therapy within the last 14 days&#xD;
&#xD;
          4. Have received a prophylactic vaccine within 14 days or received a live vaccine within&#xD;
             30 days of planned start of study therapy.&#xD;
&#xD;
          5. Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA4&#xD;
&#xD;
          6. Systemic steroids within the last 14 days&#xD;
&#xD;
          7. Use more than 2 g/day of acetaminophen.&#xD;
&#xD;
          8. Patients on immunosuppressive agents.&#xD;
&#xD;
          9. Patients receiving growth factors within the last 14 days&#xD;
&#xD;
         10. Known allergy to both penicillin and sulfa.&#xD;
&#xD;
         11. Severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
         12. Have artificial joints or implants that cannot be easily removed&#xD;
&#xD;
         13. Have any evidence of clinical or radiographic ascites.&#xD;
&#xD;
         14. Have significant and/or malignant pleural effusion&#xD;
&#xD;
         15. Have had a new pulmonary embolism, extremity deep venous thromboembolism, or portal&#xD;
             vein thrombosis within 2 months of study treatment&#xD;
&#xD;
         16. Infection with HIV or hepatitis B or C at screening&#xD;
&#xD;
         17. Significant heart disease&#xD;
&#xD;
         18. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of&#xD;
             sufficient peripheral venous access, that would affect the patient's ability to comply&#xD;
             with study visits and procedures&#xD;
&#xD;
         19. Are pregnant or breastfeeding.&#xD;
&#xD;
         20. Have rapidly progressing disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trish Brothers, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joann Santmyer, RN</last_name>
    <phone>(410) 583-2970</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Brothers, RN</last_name>
      <phone>410-614-3644</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joann Santmyer, RN</last_name>
      <phone>(410) 583-2970</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dung Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cy</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Pancreatic Vaccine</keyword>
  <keyword>GVAX</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>CRS-207</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

